openPR Logo
Press release

Biosimilar Hormones Market Size, Insights, Outlook, Overview By 2024-2033

Biosimilar Hormones Market

Biosimilar Hormones Market

The Business Research Company has updated its global market reports, featuring the latest data for 2024 and projections up to 2033

The Business Research Company offers in-depth market insights through Biosimilar Hormones Global Market Report 2024, providing businesses with a competitive advantage by thoroughly analyzing the market structure, including estimates for numerous segments and sub-segments.

Market Size And Growth Forecast:
The biosimilar hormones market size has grown exponentially in recent years. It will grow from $3.9 billion in 2023 to $4.98 billion in 2024 at a compound annual growth rate (CAGR) of 27.5%. The growth in the historic period can be attributed to rising prevalence of chronic diseases, increasing aging population, growing awareness of biosimilar hormones, expanded access to healthcare.

The biosimilar hormones market size is expected to see exponentially grown in the next few years. It will grow to $11.77 billion in 2028 at a compound annual growth rate (CAGR) of 24.0%. The growth in the forecast period can be attributed to expanding hormone targets, growing patient acceptance, advances in manufacturing, government support, growing clinical trial data, expanded access to healthcare. Major trends in the forecast period include personalized hormone replacement, product launches, pricing and access, patient-centric care.

Get Free Sample Of This Report-
https://www.thebusinessresearchcompany.com/sample.aspx?id=3432&type=smp

Market Segmentation:
The biosimilar hormones market covered in this report is segmented -

1) By Type: Teriparatide Biosimilars, Follitropin Alfa Biosimilars, Insulin Biosimilars, Somatropin Biosimilars, Other Types
2) By Application: Research & Biotechnology, Diagnostics, Biocatalysts, Therapeutics, Other Applications
3) By Distribution Channel: Hospital And Retail Pharmacy, Online Pharmacy/epharmacy, Speciality Clinics

Major Driver - Rising Demand For Hormone Biosimilarsfueled By Prevalence Of Hormonal Deficiencies
The prevalence of deficiencies in growth hormones and metabolic hormones contributes to the market. The treatments required for hormone-related conditions are evolving over the years, and the prevalence of hormonal deficiencies is generating higher demand for the hormone biosimilars market. For instance, in January 2022, according to the British Medical Journal, a UK-based peer-reviewed medical trade journal, the prevalence of GH deficiency (GHD) in children is thought to range from 1 in 3500 to 1 in 10000 across the globe. Also, in June 2022, according to a Medscape report, about 6,000 adults are expected to be diagnosed with growth hormone (GH) deficiency in the USA. The growing need to treat patients with prevailing hormonal deficiencies drives the growth of the biosimilar hormones market.

Competitive Landscape:
Major companies operating in the biosimilar hormones market include Teva Pharmaceutical Industries Ltd., Gedeon Richter Plc., Intas Pharmaceuticals Ltd., Biocon Limited, Mylan, Sanofi, Sandoz (Novartis), LG Life Sciences, Ferring Pharmaceuticals, GC Pharma, Pfizer Inc., Dr. Reddy's Laboratories, Amgen Inc., Eli Lilly and Company, Celltrion Inc., Samsungbioepis Co.Ltd, Merck & Co., Biogen Inc., Boehringer Ingelheim, Coherus BioSciences Inc., Alvotech, BioXpress Therapeutics, Cipla Limited, Lupin Ltd., Stada Arzneimittel AG, Torrent Pharmaceuticals, Zydus Cadila, Accord Healthcare, Hetero Drugs, Wockhardt

Get Access To The Full Market Report -
https://www.thebusinessresearchcompany.com/report/biosimilar-hormone-global-market-report

Top Trend - Leading Biosimilar Hormones Manufacturers Forge Partnerships And Launch In Untapped Markets
Key players operating in the biosimilar hormones market are undertaking various strategic initiatives such as new product launches in untapped regions to make the drug accessible to a large population. The companies are focusing on launching their products in various locations to boost sales and maximize profits. For instance, in February 2022, Alvotech Holdings S.A., a Luxembourg-based biopharmaceutical company specialising in the development of biosimilar medicines, announced partnerships with Fuji Pharma Co. Ltd., a Japan based pharmaceutical company, to develop biosimilar drug candidates in Japan. Through this partnership, both companies have decided to add new elements to their strategic alliance for the creation and marketing of biosimilar medicines in Japan.

The Table Of Content For The Market Report Include:
1. Executive Summary
2. Biosimilar Hormones Market Characteristics
3. Biosimilar Hormones Market Trends And Strategies
4. Biosimilar Hormones Market - Macro Economic Scenario
5. Biosimilar Hormones Market Size And Growth
…..
27. Biosimilar Hormones Market Competitor Landscape And Company Profiles
28. Key Mergers And Acquisitions
29. Future Outlook and Potential Analysis
30. Appendix

Contact us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 8897263534
Americas: +1 315 623 0293
Email: info@tbrc.info

Follow Us On:
LinkedIn:https://in.linkedin.com/company/the-business-research-company
Twitter:https://twitter.com/tbrc_info
Facebook:https://www.facebook.com/TheBusinessResearchCompany
YouTube:https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog:https://blog.tbrc.info/
Healthcare Blog:https://healthcareresearchreports.com/
Global Market Model:https://www.thebusinessresearchcompany.com/global-market-model
Latest Trending Press Releases:https://www.thebusinessresearchcompany.com/press-release.aspx

About The Business Research Company
The Business Research Company (www.thebusinessresearchcompany.com) is a market intelligence firm that pioneers in company, market, and consumer research. Located globally, TBRC's consultants specialize in various industries including manufacturing, healthcare, financial services, chemicals, and technology.

Global Market Model - World's Most Comprehensive Database
The Business Research Company's flagship product, Global Market Model (www.thebusinessresearchcompany.com/global-market-model) is a market intelligence platform covering various macroeconomic indicators and metrics across 60 geographies and 27 industries. The Global Market Model covers multi-layered datasets which help its users assess supply-demand gaps.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Biosimilar Hormones Market Size, Insights, Outlook, Overview By 2024-2033 here

News-ID: 3387514 • Views:

More Releases from The Business research company

Emerging Markets And Increasing Disposable Income Fueling Diamond Market Growth: Powering Innovation and Expansion in the Diamond Market by 2025
Emerging Markets And Increasing Disposable Income Fueling Diamond Market Growth: …
Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts. What Is the Expected CAGR for the Diamond Market Through 2025? In the past few years, there has been a stable expansion in the diamond market size. The prediction is it will increase from $1.33 billion in 2024 to $1.39 billion in 2025, boasting a compound annual growth rate
2025-2034 Nonmetallic Minerals Mining Support Activities Market Outlook: Key Drivers, Emerging Challenges, and Strategic Insights
2025-2034 Nonmetallic Minerals Mining Support Activities Market Outlook: Key Dri …
Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts. What Will the Nonmetallic Minerals Mining Support Activities Industry Market Size Be by 2025? In the past few years, there has been a robust expansion in the size of the nonmetallic minerals mining support activities market. It is projected to escalate from $34.04 billion in 2024 to $36.55 billion
Professional Street Sweeper Industry Outlook 2025-2029: Market Set to Cross $3.18 Billion Milestone
Professional Street Sweeper Industry Outlook 2025-2029: Market Set to Cross $3.1 …
Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts. How Large Will the Professional Street Sweeper Market Size By 2025? The market size of professional street sweepers has seen significant expansion in the past few years. The market, predicted to rise from $2.37 billion in 2024 to $2.5 billion in 2025, boasts a compound annual growth rate (CAGR)
Key Trends Reshaping the Industrial Wet Dust Collector Market: Advanced Filtration Technologies Empower Compliance With Environmental Standards Industry Transformation
Key Trends Reshaping the Industrial Wet Dust Collector Market: Advanced Filtrati …
Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts. Industrial Wet Dust Collector Market Size Growth Forecast: What to Expect by 2025? In recent times, there has been a robust growth in the size of the industrial wet dust collector market. It is expected to swell from $1.89 billion in 2024 to $2 billion by 2025, showing a

All 5 Releases


More Releases for Biosimilar

Key Trend Reshaping the Biosimilar Monoclonal Antibodies Market in 2025: Advance …
What Are the Projections for the Size and Growth Rate of the Biosimilar Monoclonal Antibodies Market? In recent times, the biosimilar monoclonal antibodies sector has experienced a swift expansion. The market size, which stands at $8.04 billion in 2024, is projected to climb to $9.25 billion in 2025, marking a compound annual growth rate (CAGR) of 15.1%. Factors such as expired patents, an increased understanding of biosimilars, governmental strategies, heightened financial
Key Trend Reshaping the Biosimilar Monoclonal Antibodies Market in 2025: Advance …
What Are the Projections for the Size and Growth Rate of the Biosimilar Monoclonal Antibodies Market? In recent times, the biosimilar monoclonal antibodies sector has experienced a swift expansion. The market size, which stands at $8.04 billion in 2024, is projected to climb to $9.25 billion in 2025, marking a compound annual growth rate (CAGR) of 15.1%. Factors such as expired patents, an increased understanding of biosimilars, governmental strategies, heightened financial
Biosimilar Market Treating More for Less: The Booming Infliximab Biosimilar Mark …
Infliximab Biosimilar Market worth $ XX Million by 2030 - Exclusive Report by InsightAce Analytic InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the "Global Infliximab Biosimilar Market- by Application (Crohn's Disease, Psoriatic Arthritis, Rheumatoid Arthritis, Ulcerative Colitis, Ankylosing Spondylitis, Plaque Psoriasis and Others), End User (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy and Other Direct Distribution Channels), Trends, Industry Competition Analysis, Revenue and Forecast To 2030." Get
Biosimilar Monoclonal Antibodies Market
InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the " "Global Biosimilar Monoclonal Antibodies Market by Product (infliximab, trastuzumab, rituximab, adalimumab, bevacizumab, cetuximab, ranibizumab, denosumab, eculizumab, and other pipeline products), Indication (oncology, inflammatory & autoimmune disorders, chronic diseases, blood disorders, and other indications), Clinical Trial/Pipeline Analysis, Future Trends, Industry Competition Analysis, Revenue and Forecast To 2031." The Biosimilar Monoclonal Antibodies Market Size is valued at 5.02
Infliximab Biosimilar Insight, 2023 | DelveInsight
DelveInsight's, "Infliximab Biosimilar Insight, 2023" report provides comprehensive insights about 35+ companies and 45+ marketed and pipeline drugs in Infliximab Biosimilars landscape. It covers the marketed and pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Interested to know more about the functioning of
Infliximab Biosimilar Insight, 2022 | DelveInsight
DelveInsight's, "Infliximab Biosimilar Insight, 2022" report provides comprehensive insights about 35+ companies and 45+ marketed and pipeline drugs in Infliximab Biosimilars landscape. It covers the marketed and pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Interested to know more about the functioning of